Correlation Between Johnson Johnson and Inhibikase Therapeutics
Can any of the company-specific risk be diversified away by investing in both Johnson Johnson and Inhibikase Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Johnson Johnson and Inhibikase Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Johnson Johnson and Inhibikase Therapeutics, you can compare the effects of market volatilities on Johnson Johnson and Inhibikase Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Johnson Johnson with a short position of Inhibikase Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Johnson Johnson and Inhibikase Therapeutics.
Diversification Opportunities for Johnson Johnson and Inhibikase Therapeutics
-0.56 | Correlation Coefficient |
Excellent diversification
The 3 months correlation between Johnson and Inhibikase is -0.56. Overlapping area represents the amount of risk that can be diversified away by holding Johnson Johnson and Inhibikase Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Inhibikase Therapeutics and Johnson Johnson is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Johnson Johnson are associated (or correlated) with Inhibikase Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Inhibikase Therapeutics has no effect on the direction of Johnson Johnson i.e., Johnson Johnson and Inhibikase Therapeutics go up and down completely randomly.
Pair Corralation between Johnson Johnson and Inhibikase Therapeutics
Considering the 90-day investment horizon Johnson Johnson is expected to generate 0.09 times more return on investment than Inhibikase Therapeutics. However, Johnson Johnson is 11.54 times less risky than Inhibikase Therapeutics. It trades about 0.44 of its potential returns per unit of risk. Inhibikase Therapeutics is currently generating about -0.02 per unit of risk. If you would invest 14,995 in Johnson Johnson on November 30, 2024 and sell it today you would earn a total of 1,378 from holding Johnson Johnson or generate 9.19% return on investment over 90 days.
Time Period | 3 Months [change] |
Direction | Moves Against |
Strength | Very Weak |
Accuracy | 100.0% |
Values | Daily Returns |
Johnson Johnson vs. Inhibikase Therapeutics
Performance |
Timeline |
Johnson Johnson |
Inhibikase Therapeutics |
Johnson Johnson and Inhibikase Therapeutics Volatility Contrast
Predicted Return Density |
Returns |
Pair Trading with Johnson Johnson and Inhibikase Therapeutics
The main advantage of trading using opposite Johnson Johnson and Inhibikase Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Johnson Johnson position performs unexpectedly, Inhibikase Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Inhibikase Therapeutics will offset losses from the drop in Inhibikase Therapeutics' long position.Johnson Johnson vs. Merck Company | ||
Johnson Johnson vs. Bristol Myers Squibb | ||
Johnson Johnson vs. Amgen Inc | ||
Johnson Johnson vs. Pfizer Inc |
Inhibikase Therapeutics vs. DiaMedica Therapeutics | ||
Inhibikase Therapeutics vs. Milestone Pharmaceuticals | ||
Inhibikase Therapeutics vs. Seres Therapeutics | ||
Inhibikase Therapeutics vs. Oncolytics Biotech |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..
Other Complementary Tools
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. |